logo-loader
Summit Therapeutics PLC

Summit Therapeutics advancing its pipeline of innovative antibiotics

Summit Therapeutics PLC’s (NASDAQ:SMMT) (LON:SUMM) Dr Richard Pye updates Proactive London soon after taking their next-generation antibiotic into the final and decisive stage of clinical trials.

The Phase III study of ridinilazole began last month (February).

Summit's also busy developing its pre-clinical candidate for gonorrhoea.

Quick facts: Summit Therapeutics PLC

Price: £0.22

Market: AIM
Market Cap: £34.51 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics 'taking leadership role' in development of new antibiotics

Summit Therapeutics PLC's (LON:SUMM) Dr Richard Pye speaks to Proactive London's Andrew Scott following a first quarter update on operational progress across the portfolio. Summit's currently developing three flagship treatments; Ridinilazole, designed to treat Clostridium difficile which...

on 13/6/19

2 min read